However, a recent study has shown that IDO inhibition can paradoxically protect tumor cells from the detrimental effects of T cell‐derived IFN‐γ, thereby contributing to the failure of IDO inhibitor‐based therapies [175]. The gene discussed is IFNG; the disease is neoplasm.